| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 1853- | dietFMD, | Impact of Fasting on Patients With Cancer: An Integrative Review |
| - | Review, | Var, | NA |
| 1854- | dietFMD, | How Far Are We from Prescribing Fasting as Anticancer Medicine? |
| - | Review, | Var, | NA |
| 1860- | dietFMD, | Chemo, | Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | 4T1 |
| 1843- | dietFMD, | BTZ, | Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia |
| - | in-vivo, | CLL, | NA |
| 1842- | dietFMD, | Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment |
| - | Trial, | Var, | NA |
| 1841- | dietFMD, | Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer |
| - | Trial, | Var, | NA |
| 1810- | dietKeto, | Oxy, | The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer |
| - | in-vivo, | Var, | NA |
| 1896- | dietMet, | Dietary methionine links nutrition and metabolism to the efficacy of cancer therapies |
| - | in-vivo, | CRC, | NA |
| 2170- | dietMet, | Low Protein Intake is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population |
| - | Study, | Var, | NA |
| 2271- | dietMet, | A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension |
| - | Review, | Nor, | NA |
| 2268- | dietMet, | Methionine dependency and cancer treatment |
| - | Review, | Var, | NA |
| 2263- | dietMet, | Methionine Restriction and Cancer Biology |
| - | Review, | Var, | NA |
| 2264- | dietMet, | Methionine restriction for cancer therapy: From preclinical studies to clinical trials |
| - | Review, | Var, | NA |
| 2265- | dietMet, | Cysteine supplementation reverses methionine restriction effects on rat adiposity: significance of stearoyl-coenzyme A desaturase |
| - | in-vivo, | Nor, | NA |
| 2266- | dietMet, | Cysteine dietary supplementation reverses the decrease in mitochondrial ROS production at complex I induced by methionine restriction |
| - | in-vivo, | Nor, | NA |
| 5192- | dietMet, | Intermittent methionine restriction reduces IGF‐1 levels and produces similar healthspan benefits to continuous methionine restriction |
| 5191- | dietMet, | Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade |
| - | in-vitro, | Colon, | HT29 |
| 2161- | dietP, | Plant-Based Diets and Cancer Prognosis: a Review of Recent Research |
| - | Review, | NA, | NA |
| 2165- | dietP, | SFN, | Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study |
| - | Trial, | PC, | NA |
| 2157- | dietP, | Plant-Based Diets and Disease Progression in Men With Prostate Cancer |
| - | Study, | Pca, | NA |
| 2156- | dietP, | Phytochemical-rich vegetable and fruit juice alleviates oral mucositis during concurrent chemoradiotherapy in patients with locally advanced head and neck cancer |
| - | Human, | HNSCC, | NA |
| 2155- | dietP, | Transepithelial Anti-Neuroblastoma Response to Kale among Four Vegetable Juices Using In Vitro Model Co-Culture System |
| - | in-vivo, | neuroblastoma, | Caco-2 | - | NA, | NA, | SH-SY5Y |
| 1626- | dietSTF, | dietFMD, | When less may be more: calorie restriction and response to cancer therapy |
| - | Review, | Var, | NA |
| 5070- | dietSTF, | A review of fasting effects on the response of cancer to chemotherapy |
| - | Review, | Var, | NA |
| 4159- | dietSTF, | 2DG, | CRMs, | Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms |
| - | Review, | AD, | NA |
| 3708- | dietSTF, | Fasting as a Therapy in Neurological Disease |
| 4984- | Dipy, | ATV, | Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop |
| - | in-vitro, | AML, | NA |
| 4983- | Dipy, | ATV, | Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one |
| - | Review, | Var, | NA |
| 5386- | docx, | AsP, | Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacy |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 |
| 4913- | DSF, | Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies |
| - | Review, | Var, | NA |
| 4914- | DSF, | immuno, | Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies |
| - | Review, | Var, | NA |
| 4916- | DSF, | Cu, | The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics |
| - | Review, | Var, | NA |
| 4915- | DSF, | Cu, | Disulfiram: A novel repurposed drug for cancer therapy |
| - | Review, | Var, | NA |
| 5008- | DSF, | Cu, | Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis |
| - | in-vitro, | HCC, | NA |
| - | vitro+vivo, | lymphoma, | NA |
| 5011- | DSF, | Cu, | Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens |
| - | Review, | Var, | NA |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
| 5006- | DSF, | Cu, | Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition |
| - | vitro+vivo, | lymphoma, | NA |
| 4832- | EA, | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1619- | EA, | CUR, | effect-of-the-ellagic-acid-and-curcumin-combinations-2161-0525-1000296.pdf">Antimutagenic Effect of the Ellagic Acid and Curcumin Combinations |
| - | in-vitro, | Nor, | NA |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1611- | EA, | Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues |
| - | in-vitro, | Mal, | NA |
| 1613- | EA, | Ellagitannins in Cancer Chemoprevention and Therapy |
| - | Review, | Var, | NA |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 22- | EGCG, | Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics |
| - | in-vitro, | PC, | CD133+ | - | in-vitro, | PC, | CD44+ | - | in-vitro, | PC, | CD24+ | - | in-vitro, | PC, | ESA+ |
| 645- | EGCG, | The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate |
| - | Analysis, | NA, | NA |
| 660- | EGCG, | FA, | Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| - | in-vitro, | CRC, | NA |
| 3220- | EGCG, | Dual Roles of Nrf2 in Cancer |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid